Eton Pharmaceuticals, Inc. (ETON): Price and Financial Metrics
GET POWR RATINGS... FREE!
ETON POWR Grades
- ETON scores best on the Sentiment dimension, with a Sentiment rank ahead of 74.94% of US stocks.
- ETON's strongest trending metric is Stability; it's been moving up over the last 198 days.
- ETON ranks lowest in Momentum; there it ranks in the 5th percentile.
ETON Stock Summary
- Eton Pharmaceuticals Inc's stock had its IPO on November 13, 2018, making it an older stock than merely 5.6% of US equities in our set.
- ETON's price/sales ratio is 5,125.6; that's higher than the P/S ratio of 99.56% of US stocks.
- Revenue growth over the past 12 months for Eton Pharmaceuticals Inc comes in at -95.93%, a number that bests just 0.8% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Eton Pharmaceuticals Inc are ATOM, PLXP, CRNX, CRSP, and AQB.
- ETON's SEC filings can be seen here. And to visit Eton Pharmaceuticals Inc's official web site, go to www.etonpharma.com.
ETON Stock Price Chart Interactive Chart >
ETON Price/Volume Stats
|Current price||$8.19||52-week high||$10.30|
|Prev. close||$8.48||52-week low||$4.32|
|Day high||$8.59||Avg. volume||178,375|
|50-day MA||$7.85||Dividend yield||N/A|
|200-day MA||$7.86||Market Cap||200.52M|
Eton Pharmaceuticals, Inc. (ETON) Company Bio
Eton Pharmaceuticals Inc. Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.
ETON Latest News Stream
|Loading, please wait...|
ETON Latest Social Stream
View Full ETON Social Stream
Latest ETON News From Around the Web
Below are the latest news stories about Eton Pharmaceuticals Inc that investors may wish to consider to help them evaluate ETON as an investment opportunity.
Eton Pharmaceuticals, Inc. (ETON) Q4 2020 Earnings Conference Call March 16, 2021 16:30 ET Company Participants David Krempa - Vice President, Business Development Sean Brynjelsen - Chief Executive Officer Wilson Troutman - Chief Financial Officer Paul Stickler - Senior Vice President, Sales and Marketing Conference Call Participants Andrew D’silva -...
DEER PARK, Ill., March 17, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17, 2021. Ms. Adams brings extensive commercial, operational, and leadership experience in the pharmaceutical industry. “We are pleased to have Jenn join our board. Her experience growing pharmaceutical companies and leading sales organizations will be valuable to Eton as we continue to launch products and grow our commercial organization,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. Ms. Adams’ experience includes leading and growing both Fortune 500 public and private equity-backed companie...
Eton Pharmaceuticals Earnings Report: Here’s what to expect from Stock market Insights & financial analysis
Eton Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -23.08% and -92.21%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
DEER PARK, Ill., March 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on business progress. “2020 was a transformational year for Eton and the momentum has continued through the start of 2021. In recent months, we have seen two of our products commercially launched, completed an important value-creating transaction with our neurology portfolio, and expanded our ALKINDI SPRINKLE franchise to include Canada,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “With these recent events, we believe we have a clear pathway to achieve of our goal ...
ETON Price Returns
Continue Researching ETONWant to do more research on Eton Pharmaceuticals Inc's stock and its price? Try the links below:
Eton Pharmaceuticals Inc (ETON) Stock Price | Nasdaq
Eton Pharmaceuticals Inc (ETON) Stock Quote, History and News - Yahoo Finance
Eton Pharmaceuticals Inc (ETON) Stock Price and Basic Information | MarketWatch